Overall, our findings provide a support for the combined use of lenalidomide with rituximab in the treatment of CLL patients and suggest that other treatments that increase the immunogenicity of tumor cells, for instance, by inducing the expression of ligands of NK cell receptors on leukemia cells such as histone deacetylase inhibitors [30], may be an attractive therapeutic strategy to be combined with lenalidomide. The gene discussed is KLRD1; the disease is neoplasm.